Sarepta Therapeutics’ (SRPT) Overweight Rating Reiterated at Cantor Fitzgerald

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “overweight” rating reissued by equities researchers at Cantor Fitzgerald in a report released on Tuesday,Benzinga reports. They presently have a $163.00 target price on the biotechnology company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 60.83% from the company’s current price.

Other equities analysts also recently issued research reports about the stock. Royal Bank of Canada reduced their price target on shares of Sarepta Therapeutics from $165.00 to $161.00 and set an “outperform” rating for the company in a report on Thursday, February 27th. StockNews.com downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, November 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $202.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, February 27th. HC Wainwright reaffirmed a “sell” rating and issued a $75.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, February 27th. Finally, Piper Sandler reduced their price objective on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, Sarepta Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $170.23.

Sarepta Therapeutics Stock Up 4.3 %

SRPT stock opened at $101.35 on Tuesday. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics has a 1-year low of $74.44 and a 1-year high of $173.25. The firm has a fifty day moving average price of $111.20 and a two-hundred day moving average price of $119.57. The firm has a market cap of $9.83 billion, a price-to-earnings ratio of 81.08 and a beta of 0.79.

Insider Activity at Sarepta Therapeutics

In related news, Director Claude Nicaise sold 2,491 shares of the business’s stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total value of $248,203.24. Following the completion of the sale, the director now owns 27,812 shares of the company’s stock, valued at approximately $2,771,187.68. The trade was a 8.22 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 7.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of large investors have recently added to or reduced their stakes in SRPT. Sumitomo Mitsui Trust Group Inc. boosted its position in Sarepta Therapeutics by 21.4% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,700 shares of the biotechnology company’s stock worth $212,000 after purchasing an additional 300 shares during the period. Oppenheimer Asset Management Inc. boosted its position in shares of Sarepta Therapeutics by 3.4% in the third quarter. Oppenheimer Asset Management Inc. now owns 4,457 shares of the biotechnology company’s stock valued at $557,000 after acquiring an additional 145 shares during the period. Huntington National Bank boosted its position in shares of Sarepta Therapeutics by 150.9% in the third quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 175 shares during the period. CIBC Asset Management Inc boosted its position in shares of Sarepta Therapeutics by 3.3% in the third quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock valued at $339,000 after acquiring an additional 86 shares during the period. Finally, Commerce Bank boosted its position in shares of Sarepta Therapeutics by 15.7% in the third quarter. Commerce Bank now owns 2,016 shares of the biotechnology company’s stock valued at $252,000 after acquiring an additional 274 shares during the period. Institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.